LONDON (Alliance News) - Pharma company Oncimmune Holdings PLC on Tuesday said its lung cancer blood test, EarlyCDT-Lung, has proven to be more effective than a standard risk calculator.
EarlyCDT-Lung produced a positive predictive value of 91%, this compares with a 48% positive predictive value for the standard lung cancer risk calculator.
A positive predictive value is the probability that a patient with a positive test result actually has the disease.
Moreover, only 9% patients with benign forms of the disease underwent unnecessary lung resection surgery when given the EarlyCDT-Lung test, compared to between 20% and 25% in screening trials.
"This data confirms the high specificity of the EarlyCDT-Lung blood test, which can potentially detect lung cancer four years or more, on average, before diagnosis via standard care pathways," said Oncimmune US Chief Medical Officer James Jett.
"A positive test result provides new, independent data to inform clinicians' decision-making, allowing them to 'rule-in' lung cancer and intervene earlier, while also leading to a lower resection rate for benign disease," Jett added.
Shares in Oncimmune closed down 0.8% at 128.02 pence on Tuesday.
Oncimmune (ONC)